Looking at the filing, I can identify Hemab Therapeutics Holdings, Inc. with ticker COAG on the Nasdaq Global Select Market, filing a 10-Q for the quarterly period ended June 30, 2026. Let me extract the substantive disclosure content carefully. The filing does contain substantive content including company identity, share count, filing status classifications, product pipeline references (sutacimig, HMB-003, Glanzmann thrombasthenia), and risk factor summaries. This clears the 150-word threshold.

Hemab Therapeutics Holdings, Inc. filed its Form 10-Q with the U.S. Securities and Exchange Commission on August 11, 2026, covering the quarterly period ended June 30, 2026, disclosing its financial condition, pipeline status, and risk factors as a clinical-stage biopharmaceutical company.

Key Highlights

  • Share count: As of July 31, 2026, the company had 46,712,117 shares of common stock, $0.0001 par value per share, outstanding.
  • Exchange listing: Common stock trades on the Nasdaq Global Select Market under the symbol COAG.
  • Company classification: The registrant is designated as a non-accelerated filer, smaller reporting company, and emerging growth company under SEC definitions.
  • Lead pipeline asset: The company disclosed plans for a Phase 3 clinical trial of sutacimig in patients with Glanzmann thrombasthenia.
  • Early-stage candidate: The company referenced plans for first in-human studies of HMB-003.
  • No approved products: According to the filing's risk factor summary, the company "has no products approved for sale" and "has incurred significant losses since our inception."

Hemab Therapeutics: Pipeline, Financial Status, and Key Disclosures for Q2 2026

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG), a Delaware-incorporated biopharmaceutical company headquartered at 101 Main Street, Suite 1220, Cambridge, Massachusetts, filed its quarterly report for the period ended June 30, 2026. The filing confirmed that the company had 46,712,117 shares of common stock outstanding as of July 31, 2026, with a par value of $0.0001 per share. The company has not elected to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act.

The filing disclosed that Hemab's lead product candidate, sutacimig, is being developed for patients with Glanzmann thrombasthenia, a rare bleeding disorder, with a Phase 3 clinical trial planned. A second candidate, HMB-003, is progressing toward first in-human studies, according to statements made in the forward-looking disclosures section of the report. The company noted that forward-looking statements, including those about clinical trial timing and regulatory progress, involve "substantial risk and uncertainties" and are subject to the cautionary language set out in the filing.

According to the risk factor summary included in the quarterly report, Hemab "has incurred significant losses since our inception and has no products approved for sale." The company's risk disclosures also addressed reliance on third parties for clinical trial conduct and manufacturing, capital requirements, and the potential need for additional financing. The filing confirmed that the company is not a shell company and has been subject to SEC reporting requirements for the past 90 days, with all required reports filed during the preceding 12 months.

What Was Disclosed

Hemab Therapeutics Holdings, Inc. submitted its 10-Q for the quarter ended June 30, 2026, reporting 46,712,117 shares outstanding, a planned Phase 3 trial for sutacimig in Glanzmann thrombasthenia, early-stage development of HMB-003, and an acknowledgment of accumulated losses with no approved products to date.